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Abstract
Background:  Diffuse microvascular bleeding remains a common problem after cardiac
procedures.
Systemic use of antifibrinolytic reduces the postoperative blood loss.
The purpose of this study was to examine the effectiveness of local application of tranexamic acid
to reduce blood loss after coronary artery bypass grafting (CABG).
Methods: Thirty eight patients scheduled for primary isolated coronary artery bypass grafting
were included in this double blind, prospective, randomized, placebo controlled study.
Tranexamic acid (TA) group (19 patients) received 1 gram of TA diluted in 100 ml normal saline.
Placebo group (19 patients) received 100 ml of normal saline only. The solution was purred in the
pericardial and mediastinal cavities.
Results: Both groups were comparable in their baseline demographic and surgical characteristics.
During the first 24 hours post-operatively, cumulative blood loss was significantly less in TA group
(median of 626 ml) compared to Placebo group (median of 1040 ml) (P = 0.04). There was no
significant difference in the post-op Packed RBCs transfusion between both groups (median of one
unit in each) (P = 0.82). Significant less platelets transfusion required in TA group (median zero unit)
than in placebo group (median 2 units) (P = 0.03). Apart from re-exploration for excessive surgical
bleeding in one patient in TA group, no difference was found in morbidity or mortality between
both groups.
Conclusion: Topical application of tranexamic acid in patients undergoing primary coronary
artery bypass grafting led to a significant reduction in postoperative blood loss without adding extra
risk to the patient.
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Introduction
Coagulopathy remains a common problem after coronary
artery bypass Grafting (CABG) using cardiopulmonary
bypass (CPB). It results from many factors like thrombo-
cytopenia, acquired platelet dysfunction, clotting factors
loss, free heparin, and increased fibrinolysis [1-3]. Lem-
mer and Colleagues [4] found that extracorporeal circula-
tion results in significant fibrinolysis, as reflected by
increased concentrations of plasmin and fibrin degrada-
tion products (FDP), both of which have deleterious
effects on platelet function. Re-exploration for bleeding
following cardiac surgery with CPB was reported to be in
the range of 2–7%. Of these, 50–80% was found to be
medical rather than surgical bleeding [5]. Fibrinolysis was
found to be responsible for 25–45% of significant post
bypass bleeding [6]. Many antifibrinolytic agents have
been used to diminish post-bypass bleeding. These
include ε Aminocaproic acid [5], aprotinin [7], and Tran-
examic acid (TA) [8]. Tranexamic acid has been found to
bind to lysine binding sites of plasmin and plasminogen.
Saturation of these sites displaces plasminogen from the
fibrin surface thus inhibiting fibrinolysis [9]. TA has been
used both systemically and topically. Intravenous TA
administration increased the risk of thromoembolic com-
plications and consequently early graft closure in coro-
nary artery bypass grafting [10]. When used topically, TA
was found effective in controlling bleeding in patients
with hemorrhagic diathesis and in patients who were
being treated with anticoagulants pre-operatively. Topical
TA has also been successfully used in controlling bleeding
in bladder, gynaecologic, oral, and otolaryngeal surgeries
[11-13].
This prospective, double-blind, randomized, placebo-
controlled study was designed to investigate the effect of
topical TA in reducing postoperative blood loss after cor-
onary artery bypass Grafting.
Methods
With institutional ethics committee approval, all patients
scheduled for primary isolated elective CABG at North
West Armed Forces Hospital, Tabuk, Saudi Arabia, during
the period from March 2004 to November 2005, were
scrutinized for eligibility enrolment. Our exclusions crite-
ria included patients who had combined procedure; redo
surgery, bleeding diathesis (Haemophilia or platelet
count < 100 × 109 L-1), renal failure (Creatinine > 160 mg/
dl), known allergy to TA, recent (<7 days before surgery)
intake of anti-platelets (e.g. Aspirin, non-steroidal anti-
inflammatory drugs) or Heparin administration within
48 hours of operation.
Thirty eight patients met the requirements for inclusion,
and informed consent was obtained from all of them. The
patients were randomly allocated into one of the two
groups. Group I (TA group) included 19 patients who
received 1 gm of TA diluted in 100 ml normal saline.
Group II (Placebo group) included 19 patients who
received 100 ml normal saline as placebo. The solution
was purred in the pericardial and mediastinal cavities
before closure of the strenotomy while clamping the chest
tubes. These clamps were released once the closure of the
strenotomy was completed.
The study was carried out as a prospective randomized,
double blind investigation. Randomization was carried
out with random-number tables by a research pharmacist
who prepared the two solutions in two identical bottles
and delivered to the operating theatre. Neither the sur-
geon, assistant, anaesthetist, scrub nurse nor the per-
fusionist knew the composition of the solution
administered. Only two cardiac surgeons were responsi-
ble for the surgical haemostasis.
The anaesthetic management and conduct of CPB were
standardized. The patients were premedicated using
Nitrozepam 0.1 mg/kg tablet the night of the operation,
and morphine 0.15 mg/kg intramuscular half an hour
before operation. Induction was done using Fentanyl 2–5
ug/kg, Propofol 1–2 mg/kg, and Pancronium 0.1 mg/kg.
Anaesthesia was maintained by using Sevoflurane 0.5–
1%, Pancronium 0.06 mg/kg, Fentanyl 1–2 ug/kg during
cardiopulmonary bypass time. All patients received
Heparin 300 units/Kg before CPB to achieve target acti-
vated clotting time (ACT) of ≥ 480 seconds. During CPB,
extra heparin was given as needed to maintain the target
ACT. After separation from CPB, heparin was reversed
using protamine sulphate in the dose of 1 mg/100 units of
heparin to achieve target ACT 80–120 seconds.
After the patient was transferred to the intensive care unit
(ICU), continuous low grade suction (10–15 cm H2O)
was applied together with periodic milking of the drains.
Haemoglobin level (Hb), Hematocrite value (Hct %),
Platelet count, International Normalized Ratio (INR),
Partial Thromboplastin time (PTT), and Fibrinogen level
were measured before the operation and when the
patients arrived at the intensive care unit. The drainage of
the chest tubes was measured hourly and were removed
when the total drainage volume of 80–100 ml over the
previous12 hours and of serous color. Uniform transfu-
sion protocol was applied to all patients. Blood and blood
components were administered only when the hemat-
ocrite level < 24% or the haemoglobin level ≤ 8.0 gm/dL
in the postoperative period. Shed mediastinal blood was
not transfused into any patient during this study.
Beside patients' demographics, the numbers of grafts, left
internal mammary artery (LIMA) use, cross clamp time,
duration of CPB, incidence of reoperation for bleeding,Journal of Cardiothoracic Surgery 2009, 4:25 http://www.cardiothoracicsurgery.org/content/4/1/25
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ICU stay and the length of hospital stay (LOS) were
recorded for all patients.
Statistical Analysis
Parametric data were analysed using 2-tailed unpaired stu-
dent t test, and presented as mean ± standard deviation.
Data analysis for blood loss and requirements for blood
products was done using non-parametric tests (Mann-
Whitney Rank Sum test) using Sigma Stat (v 3.5, Systat
Software San Jose, California, USA), and expressed as
median and range. Values of p less than 0.05 were consid-
ered significant.
Results
Both groups were comparable with respect to baseline
demographic data and there was no statistically signifi-
cant difference in the prevalence of risk factors between
both groups as shown in Table 1.
The two groups were matched with regard to intraopera-
tive data; use of left internal mammary artery, average
number of distal anastmoses, cross clamp time, cardiop-
ulmonary bypass (CPB) time and duration of the opera-
tion (Table 2). There was no bias in the distribution of the
anaesthesiologist and surgeons between the two groups.
Pre and postoperative haemoglobin concentrations,
hematocrit concentrations, platelet counts, international
normalized ratio, partial thromboplastin times and
fibrinogen level were not significantly different between
the two groups (Tables 3 &4). Chest tube drainage in the
first 24 hours was significantly less in TA group (median
of 626 ml) than in the placebo group (median of 1040
ml) (P = 0.04). This represented about 37% decrease in
the blood loss. The median total post-operative chest tube
drainage was 656 ml (range 248–2105) in TA group and
1056 ml (range 210–3010) in the placebo group, which
represents 32% reduction in total bleeding (Figures 1 &2).
There was no significant difference in the post-op packed
red blood cells (PRBCs) transfusion between both groups
(median of one unit in each) (P = 0.82). Also there was no
significant difference in regard Fresh Frozen Plasma (FFP)
transfusion between both groups (median of zero unit in
TA vs. two units in placebo) (P = 0.42). Significant more
platelets transfusion required in the Placebo group
(median 2 units) than in TA group (median zero unit) (P
= 0.03) (Figure 3). Troponin I level recorded a lower level
in TA group (2.4 ± 3.8) than Placebo group (4.7 ± 2.0) (P
= 0.68). There was no post-op myocardial infarction
encountered in either group. Although there was no dif-
ference in intubation time between both groups, Placebo
group patients stayed significantly longer in ICU (49 ± 20
Hrs) than the TA patients (29 ± 26) (P = 0.02). Total
length of Hospital stay was comparable in both groups
(Table 5). Apart from re-exploration for excessive surgical
bleeding in one patient in the TA group (due to branch
bleeding of one of the grafts), no difference was found in
morbidity or mortality between the two groups. There
were no deaths in either group.
Discussion
Intravenous use of aprotinin, tranexamic acid and amino-
caproic acid has proved to be effective in decreasing post-
operative bleeding in both primary and redo coronary
artery bypass grafting. However, the risk of death is con-
Table 1: Patients' Demographics.
TA (n = 19) Placebo (n = 19) P-Value
Age (y) 55 ± 11 60 ± 7 0.17
M/F 18/1 18/1 1.0
Wt. (Kg) 73 ± 15 71 ± 14 0.74
BMI 27 ± 4 27 ± 4 1.0
Smoking 6 (31.5%) 6 (31.5%) 1.0
Diabetes 7 (37%) 10 (53%) 0.42
Hypertension 7 (37%) 12 (63%) 0.17
Hyperchol 3 (16%) 0 (0%) 0.08
COPD 1 (5%) 1 (5%) 1.0
RF 0 (0%) 1 (5%) 0.33
PVD 3 (16%) 0 (0%) 0.08
Previous MI 4 (21%) 6 (31.5%) 0.42
LVEF 48 ± 10 46 ± 10 0.49
Euroscore 2.3 ± 1.7 2.5 ± 1.6 0.58
Values are means ± SD or No.(%) where shown.
M/F: Male/Female
Wt.: Weight
BMI: Body Mass Index
COPD: Chronic Obstructive Pulmonary Disease
RF: Renal Failure
Hyperchol: Hypercholesterolmia
PVD: Peripheral Vascular Disease
MI: Myocardial Infarction
LVEF: Left Ventricular Ejection Fraction
Post-op Blood Loss/Hour Figure 1
Post-op Blood Loss/Hour. Our study demonstrates that 
pouring of one gram of TA into the pericardial cavity after 
CABG, significantly reduced post-operative blood loss in the 
first 24 hours after surgery (37%) with the maximum reduc-
tion at the 3rd hour (66%).Journal of Cardiothoracic Surgery 2009, 4:25 http://www.cardiothoracicsurgery.org/content/4/1/25
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sistently higher with use of aprotinin than with tran-
examic acid or aminocaproic acid [14].
In the large International Multi-center Aprotinin Graft
Patency Experience (IMAGE) study, no statistically signif-
icant difference in graft occlusion could be found between
patients given Aprotinin and controls when the results
were adjusted for risk factors known to be associated with
graft failure [15]. Therefore, the benefit of antifibrinolytic
agents must be always weighted against a possible
increase risk of thrombo-embolic complications that
might lead to early graft closure. Moreover, these patients
are at increase risk of cerebral, pulmonary, mesenteric and
retinal thrombosis.
Following the success of systemic use of Aprotinin and
Tranexamic acid in controlling post-CABG bleeding, trials
for topical use were initiated by Tatar et al [16] in 1993,
who reported reduced post-operative blood loss and the
need for transfusion after topical Aprotinin use in CABG
patients. Similar results were described by O'Regan and
his colleagues [17] and Khalil et al [18]. This encouraged
De Bonis group [19] in 2000 to start topical use of TA.
They conducted a prospective randomized, double
blinded study on 40 patients who had primary CABG.
They reported blood loss significantly diminished by 36%
during the first 3 hours but not during the following 21
hours after operation compared to the placebo group. Our
study demonstrates that pouring of one gram of TA into
the pericardial cavity after CABG, significantly reduced
post-operative blood loss in the first 24 hours after surgery
(37%) with the maximum reduction at the 3rd hour
(66%). Abdul Azem and his colleagues [20] in 2006
described similar results in 100 patients underwent vari-
ous open heart procedures. In contradictory to our find-
ings, Yasim and his group [21] did not find a statistically
significant reduction in post-operative bleeding after top-
ical application of Aprotinin and Tranexamic acid.
In our study the overall post-operative bleeding was mod-
est in both groups and this could be explained by the tight
inclusion criteria, meticulous surgical hemostasis, normo-
thermic CPB and the use of LIMA alone as a pedicle graft
in all patients. Therefore, despite the significant reduction
of post-operative bleeding in TA group, the effect of its
topical use might be masked by those factors. A greater
Post-op Blood Loss/24 hours and total Figure 2
Post-op Blood Loss/24 hours and total. Chest tube 
drainage in the first 24 hours was significantly less in TA 
group (median of 626 ml) than in the placebo group (median 
of 1040 ml) (P = 0.04). This represented about 37% decrease 
in the blood loss. The median total post-operative chest tube 
drainage was 656 ml (range 248–2105) in TA group and 1056 
ml (range 210–3010) in the placebo group, which represents 
32% reduction in total bleeding.
Table 2: Intra-operative Data.
TA Placebo P-Value
Graft/pt 2.8 ± 1.1 2.9 ± 1.0 0.64
LIMA 100% 100% 1.0
CX time (min) 72 ± 17 75 ± 20 0.09
TBT (min) 100 ± 28 97 ± 28 0.07
Values are means ± SD or (%) where shown.
LIMA: Left Internal Mammary Artery.
CX Time: Cross Clamp time.
TBT: Total Bypass time.
Table 3: Pre-operative Hematological Profile.
TA Placebo P-Value
Platelets 265 ± 119 156 ± 71 0.77
Hb (gm/dl) 14 ± 1.0 14 ± 1.3 0.08
Hct (%) 39 ± 2.8 41 ± 3.7 0.15
INR 1.1 ± 0.3 1.0 ± 0.2 0.23
PTT 31.2 ± 4.8 33.6 ± 3.5 0.34
Fibrinogen 362 ± 163 438 ± 158 0.46
Values are means ± SD where shown.
Hb: Hemoglobin.
Hct: Hematocrite Value.
INR: International Normalized Ratio.
PTT: Partial Thromoplastin Time.
Table 4: Post-operative Hematological Profile.
TA Placebo P-Value
Platelets 192 ± 64 196 ± 68 0.86
Hb (gm/dl) 10 ± 1.3 10 ± 1.3 0.39
Hct (%) 29 ± 3.8 30 ± 3.9 0.39
INR 1.3 ± 0.3 1.2 ± 0.4 0.18
PTT 41.2 ± 5.4 45.6 ± 7.4 0.22
Fibrinogen 239 ± 49 359 ± 202 0.15
Values are means ± SD where shown.
Hb: Hemoglobin.
Hct: Hematocrite Value.
INR: International Normalized Ratio.
PTT: Partial Thromoplastin Time.Journal of Cardiothoracic Surgery 2009, 4:25 http://www.cardiothoracicsurgery.org/content/4/1/25
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effect of topical TA in reducing blood loss could be possi-
bly evident in more prolonged and complex procedures
with a higher risk of bleeding.
The use of blood products was not significantly different
between both De Bonis' groups [19], while we had a sig-
nificant reduction only in platelet transfusion and Abdul
Azm [20] had a significant reduction only in packed cells
use in TA group. This difference in reports might be
explained by the difference in number of patients, type of
operations and transfusion protocols used in each study.
The advantage of topical use of antifibrinolytic drugs after
open heart surgery, in reducing post-operative bleeding
and transfusion requirement, needs further clinical trials
using larger number of patients [22].
Limitation of the study
We did not measure the level of TA in the serum or in the
pericardial cavity. The number of the patients was rela-
tively small and the inclusion criteria with strictly tight.
Larger multi-center prospective control trials using larger
dose of TA are needed to address its topical effect in pro-
cedures with higher risk of bleeding.
Conclusion
Topical use of Tranexamic acid into the pericardial cavity
in patients undergoing primary coronary artery bypass
grafting significantly reduces postoperative bleeding and
platelet transfusion without adding extra risk to the
patient. Consequently Tranexamic acid could be advo-
cated for routine use topically in patients undergoing cor-
onary artery bypass grafting.
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